
Danaher (DHR) Stock Forecast & Price Target
Danaher (DHR) Analyst Ratings
Bulls say
Danaher demonstrates a strong positive outlook supported by an increase in performance obligations from $4.5 billion in 1Q25 to $4.9 billion in 2Q25, which indicates robust demand for its products. The company is confident in achieving a growth rate of approximately 4.5% in its Life Sciences segment during 4Q25, driven by favorable comparisons in genomics and successful new product launches. Additionally, the expected revenue from Cepheid Respiratory, estimated between $300 million to $500 million in the upcoming quarters, further highlights the potential for substantial earnings growth amidst a strong operational performance.
Bears say
Danaher's anticipated recognition of 46% of its 2Q25 obligations as revenue within the next 12 months represents a decline from the previous quarter's 48%, indicating weakening short-term revenue growth prospects. The company faces significant risks stemming from geopolitical disruptions, foreign exchange volatility, potential underperformance in critical high-growth markets, particularly in China, and revisions to projected end-market growth rates. Furthermore, despite a slightly below-expected revenue guidance for Biotechnology and Life Sciences in 3Q25, confidence in the second half is tempered by uncertainties in macroeconomic conditions and market recovery.
This aggregate rating is based on analysts' research of Danaher and is not a guaranteed prediction by Public.com or investment advice.
Danaher (DHR) Analyst Forecast & Price Prediction
Start investing in Danaher (DHR)
Order type
Buy in
Order amount
Est. shares
0 shares